Assuring Medicaid Beneficiaries Access to Hepatitis C (HCV) Drugs
The Centers for Medicare & Medicaid Services (CMS) remains committed to Medicaid beneficiaries continuing to have access to needed prescribed medications, a commitment we know that states share. We have issued a letter to advise states (PDF, 155.54 KB) on the coverage of drugs for Medicaid beneficiaries living with hepatitis C virus (HCV) infections. Specifically, this letter addresses utilization of the direct-acting antiviral (DAA) drugs approved by the Food and Drug Administration (FDA) for the treatment of chronic HCV infected patients.
Manufacturers have a role to play in ensuring access and affordability to these medications. CMS has sent a letter to the manufacturers of these HCV medications, asking them to provide information regarding any value-based purchasing arrangements they offer for these drugs so that states might be able to participate in such arrangements. Please see below for the letter sent to each of the manufacturers.